GSK Quote, Financials, Valuation and Earnings

BioNTech SE has a net margin of 5.1% compared to GSK PLC's net margin of 21.81%. GSK PLC's return on equity of 19.22% beat BioNTech SE's return on equity of -3.39%.

GSK PLC has a consensus price target of $43.55, signalling upside risk potential of 29.6%. On the other hand BioNTech SE has an analysts' consensus of $139.19 which suggests that it could grow by 49.47%. Given that BioNTech SE has higher upside potential than GSK PLC, analysts believe BioNTech SE is more attractive than GSK PLC.

GSK PLC has a beta of 0.579, which suggesting that the stock is 42.135% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.069, suggesting its more volatile than the S&P 500 by 6.943%.

GSK PLC has a quarterly dividend of $0.40 per share corresponding to a yield of 4.63%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GSK PLC pays 94.91% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend. GSK PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

GSK PLC quarterly revenues are $10.4B, which are larger than BioNTech SE quarterly revenues of $1.3B. GSK PLC's net income of $530.1M is higher than BioNTech SE's net income of $276.6M. Notably, GSK PLC's price-to-earnings ratio is 21.22x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK PLC is 1.73x versus 7.52x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.

Haleon PLC has a net margin of 5.1% compared to GSK PLC's net margin of 8.37%. GSK PLC's return on equity of 19.22% beat Haleon PLC's return on equity of 8.91%.

GSK PLC has a consensus price target of $43.55, signalling upside risk potential of 29.6%. On the other hand Haleon PLC has an analysts' consensus of $10.71 which suggests that it could grow by 11.19%. Given that GSK PLC has higher upside potential than Haleon PLC, analysts believe GSK PLC is more attractive than Haleon PLC.

GSK PLC has a beta of 0.579, which suggesting that the stock is 42.135% less volatile than S&P 500. In comparison Haleon PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

GSK PLC has a quarterly dividend of $0.40 per share corresponding to a yield of 4.63%. Haleon PLC offers a yield of 1.64% to investors and pays a quarterly dividend of $0.05 per share. GSK PLC pays 94.91% of its earnings as a dividend. Haleon PLC pays out 39.53% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

GSK PLC quarterly revenues are $10.4B, which are larger than Haleon PLC quarterly revenues of $3.5B. GSK PLC's net income of $530.1M is higher than Haleon PLC's net income of $295.8M. Notably, GSK PLC's price-to-earnings ratio is 21.22x while Haleon PLC's PE ratio is 23.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK PLC is 1.73x versus 3.08x for Haleon PLC. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 5.1% compared to GSK PLC's net margin of -117.16%. GSK PLC's return on equity of 19.22% beat Moderna's return on equity of -29.09%.

GSK PLC has a consensus price target of $43.55, signalling upside risk potential of 29.6%. On the other hand Moderna has an analysts' consensus of $52.05 which suggests that it could grow by 112.44%. Given that Moderna has higher upside potential than GSK PLC, analysts believe Moderna is more attractive than GSK PLC.

GSK PLC has a beta of 0.579, which suggesting that the stock is 42.135% less volatile than S&P 500. In comparison Moderna has a beta of 2.231, suggesting its more volatile than the S&P 500 by 123.128%.

GSK PLC has a quarterly dividend of $0.40 per share corresponding to a yield of 4.63%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GSK PLC pays 94.91% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. GSK PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

GSK PLC quarterly revenues are $10.4B, which are larger than Moderna quarterly revenues of $956M. GSK PLC's net income of $530.1M is higher than Moderna's net income of -$1.1B. Notably, GSK PLC's price-to-earnings ratio is 21.22x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK PLC is 1.73x versus 2.97x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Novavax has a net margin of 5.1% compared to GSK PLC's net margin of -91.76%. GSK PLC's return on equity of 19.22% beat Novavax's return on equity of --.

GSK PLC has a consensus price target of $43.55, signalling upside risk potential of 29.6%. On the other hand Novavax has an analysts' consensus of $16.43 which suggests that it could grow by 202.83%. Given that Novavax has higher upside potential than GSK PLC, analysts believe Novavax is more attractive than GSK PLC.

GSK PLC has a beta of 0.579, which suggesting that the stock is 42.135% less volatile than S&P 500. In comparison Novavax has a beta of 3.148, suggesting its more volatile than the S&P 500 by 214.784%.

GSK PLC has a quarterly dividend of $0.40 per share corresponding to a yield of 4.63%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GSK PLC pays 94.91% of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend. GSK PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

GSK PLC quarterly revenues are $10.4B, which are larger than Novavax quarterly revenues of $88.3M. GSK PLC's net income of $530.1M is higher than Novavax's net income of -$81M. Notably, GSK PLC's price-to-earnings ratio is 21.22x while Novavax's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK PLC is 1.73x versus 1.24x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.